Cargando…

Targeted quantification of N-1-(carboxymethyl) valine and N-1-(carboxyethyl) valine peptides of β-hemoglobin for better diagnostics in diabetes

BACKGROUND: N-1-(Deoxyfructosyl) valine (DFV) β-hemoglobin (β-Hb), commonly referred as HbA1c, is widely used diagnostic marker in diabetes, believed to provide glycemic status of preceding 90–120 days. However, the turnover of hemoglobin is about 120 days, the DFV-β-Hb, an early and reversible glyc...

Descripción completa

Detalles Bibliográficos
Autores principales: Jagadeeshaprasad, Mashanipalya G., Batkulwar, Kedar B., Meshram, Nishita N., Tiwari, Shalbha, Korwar, Arvind M., Unnikrishnan, Ambika G., Kulkarni, Mahesh J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4812615/
https://www.ncbi.nlm.nih.gov/pubmed/27030792
http://dx.doi.org/10.1186/s12014-016-9108-y
_version_ 1782424199468417024
author Jagadeeshaprasad, Mashanipalya G.
Batkulwar, Kedar B.
Meshram, Nishita N.
Tiwari, Shalbha
Korwar, Arvind M.
Unnikrishnan, Ambika G.
Kulkarni, Mahesh J.
author_facet Jagadeeshaprasad, Mashanipalya G.
Batkulwar, Kedar B.
Meshram, Nishita N.
Tiwari, Shalbha
Korwar, Arvind M.
Unnikrishnan, Ambika G.
Kulkarni, Mahesh J.
author_sort Jagadeeshaprasad, Mashanipalya G.
collection PubMed
description BACKGROUND: N-1-(Deoxyfructosyl) valine (DFV) β-hemoglobin (β-Hb), commonly referred as HbA1c, is widely used diagnostic marker in diabetes, believed to provide glycemic status of preceding 90–120 days. However, the turnover of hemoglobin is about 120 days, the DFV-β-Hb, an early and reversible glycation product eventually may undergo irreversible advanced glycation modifications such as carboxymethylation or carboxyethylation. Hence quantification of N-1-(carboxymethyl) valine (CMV) and N-1-(carboxyethyl) valine (CEV) peptides of β-Hb would be useful in assessing actual glycemic status. RESULTS: Fragment ion library for synthetically glycated peptides of hemoglobin was generated by using high resolution–accurate mass spectrometry (HR/AM). Using parallel reaction monitoring, deoxyfructosylated, carboxymethylated and carboxyethylated peptides of hemoglobin were quantified in clinical samples from healthy control, pre-diabetes, diabetes and poorly controlled diabetes. For the first time, we report N-1-β-valine undergoes carboxyethylation and mass spectrometric quantification of CMV and CEV peptides of β-hemoglobin. Carboxymethylation was found to be the most abundant modification of N-1-β-valine. Both CMV-β-Hb and CEV-β-Hb peptides showed better correlation with severity of diabetes in terms of fasting glucose, postprandial glucose and microalbuminuria. CONCLUSIONS: This study reports carboxymethylation as a predominant modification of N-1-β-valine of Hb, and quantification of CMV-β-Hb and CEV-β-Hb could be useful parameter for assessing the severity of diabetes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12014-016-9108-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4812615
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48126152016-03-31 Targeted quantification of N-1-(carboxymethyl) valine and N-1-(carboxyethyl) valine peptides of β-hemoglobin for better diagnostics in diabetes Jagadeeshaprasad, Mashanipalya G. Batkulwar, Kedar B. Meshram, Nishita N. Tiwari, Shalbha Korwar, Arvind M. Unnikrishnan, Ambika G. Kulkarni, Mahesh J. Clin Proteomics Research BACKGROUND: N-1-(Deoxyfructosyl) valine (DFV) β-hemoglobin (β-Hb), commonly referred as HbA1c, is widely used diagnostic marker in diabetes, believed to provide glycemic status of preceding 90–120 days. However, the turnover of hemoglobin is about 120 days, the DFV-β-Hb, an early and reversible glycation product eventually may undergo irreversible advanced glycation modifications such as carboxymethylation or carboxyethylation. Hence quantification of N-1-(carboxymethyl) valine (CMV) and N-1-(carboxyethyl) valine (CEV) peptides of β-Hb would be useful in assessing actual glycemic status. RESULTS: Fragment ion library for synthetically glycated peptides of hemoglobin was generated by using high resolution–accurate mass spectrometry (HR/AM). Using parallel reaction monitoring, deoxyfructosylated, carboxymethylated and carboxyethylated peptides of hemoglobin were quantified in clinical samples from healthy control, pre-diabetes, diabetes and poorly controlled diabetes. For the first time, we report N-1-β-valine undergoes carboxyethylation and mass spectrometric quantification of CMV and CEV peptides of β-hemoglobin. Carboxymethylation was found to be the most abundant modification of N-1-β-valine. Both CMV-β-Hb and CEV-β-Hb peptides showed better correlation with severity of diabetes in terms of fasting glucose, postprandial glucose and microalbuminuria. CONCLUSIONS: This study reports carboxymethylation as a predominant modification of N-1-β-valine of Hb, and quantification of CMV-β-Hb and CEV-β-Hb could be useful parameter for assessing the severity of diabetes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12014-016-9108-y) contains supplementary material, which is available to authorized users. BioMed Central 2016-03-29 /pmc/articles/PMC4812615/ /pubmed/27030792 http://dx.doi.org/10.1186/s12014-016-9108-y Text en © Jagadeeshaprasad et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Jagadeeshaprasad, Mashanipalya G.
Batkulwar, Kedar B.
Meshram, Nishita N.
Tiwari, Shalbha
Korwar, Arvind M.
Unnikrishnan, Ambika G.
Kulkarni, Mahesh J.
Targeted quantification of N-1-(carboxymethyl) valine and N-1-(carboxyethyl) valine peptides of β-hemoglobin for better diagnostics in diabetes
title Targeted quantification of N-1-(carboxymethyl) valine and N-1-(carboxyethyl) valine peptides of β-hemoglobin for better diagnostics in diabetes
title_full Targeted quantification of N-1-(carboxymethyl) valine and N-1-(carboxyethyl) valine peptides of β-hemoglobin for better diagnostics in diabetes
title_fullStr Targeted quantification of N-1-(carboxymethyl) valine and N-1-(carboxyethyl) valine peptides of β-hemoglobin for better diagnostics in diabetes
title_full_unstemmed Targeted quantification of N-1-(carboxymethyl) valine and N-1-(carboxyethyl) valine peptides of β-hemoglobin for better diagnostics in diabetes
title_short Targeted quantification of N-1-(carboxymethyl) valine and N-1-(carboxyethyl) valine peptides of β-hemoglobin for better diagnostics in diabetes
title_sort targeted quantification of n-1-(carboxymethyl) valine and n-1-(carboxyethyl) valine peptides of β-hemoglobin for better diagnostics in diabetes
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4812615/
https://www.ncbi.nlm.nih.gov/pubmed/27030792
http://dx.doi.org/10.1186/s12014-016-9108-y
work_keys_str_mv AT jagadeeshaprasadmashanipalyag targetedquantificationofn1carboxymethylvalineandn1carboxyethylvalinepeptidesofbhemoglobinforbetterdiagnosticsindiabetes
AT batkulwarkedarb targetedquantificationofn1carboxymethylvalineandn1carboxyethylvalinepeptidesofbhemoglobinforbetterdiagnosticsindiabetes
AT meshramnishitan targetedquantificationofn1carboxymethylvalineandn1carboxyethylvalinepeptidesofbhemoglobinforbetterdiagnosticsindiabetes
AT tiwarishalbha targetedquantificationofn1carboxymethylvalineandn1carboxyethylvalinepeptidesofbhemoglobinforbetterdiagnosticsindiabetes
AT korwararvindm targetedquantificationofn1carboxymethylvalineandn1carboxyethylvalinepeptidesofbhemoglobinforbetterdiagnosticsindiabetes
AT unnikrishnanambikag targetedquantificationofn1carboxymethylvalineandn1carboxyethylvalinepeptidesofbhemoglobinforbetterdiagnosticsindiabetes
AT kulkarnimaheshj targetedquantificationofn1carboxymethylvalineandn1carboxyethylvalinepeptidesofbhemoglobinforbetterdiagnosticsindiabetes